Kenneth J Mukamal1. 1. Beth Israel Deaconess Medical Center, General Medicine, Brookline, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Dementia is rapidly growing as sources of morbidity and mortality as the US population ages, but its pathophysiology remains poorly understood. As a result, no disease-modifying treatments currently exist. We review the evidence that nonesterified fatty acids may play a key role in this condition. RECENT FINDINGS: Nonesterified fatty acids appear to influence several pathways leading to dementia. In addition to their vascular effects, these moieties cross the blood-brain barrier, where they are toxic to several cell types. They may also influence insulin metabolism in the brain directly and indirectly, and some drugs that lower circulating levels appear to slow cognitive decline and brain atrophy in diabetes. SUMMARY: Nonesterified fatty acids may contribute to dementia, much as they do to diabetes and cardiovascular disease. Several therapeutic agents lower circulating levels of nonesterified fatty acids and should be tested for their potential preventive effects on cognitive decline in healthy populations before irreversible neuronal attrition occurs.
PURPOSE OF REVIEW: Dementia is rapidly growing as sources of morbidity and mortality as the US population ages, but its pathophysiology remains poorly understood. As a result, no disease-modifying treatments currently exist. We review the evidence that nonesterified fatty acids may play a key role in this condition. RECENT FINDINGS:Nonesterified fatty acids appear to influence several pathways leading to dementia. In addition to their vascular effects, these moieties cross the blood-brain barrier, where they are toxic to several cell types. They may also influence insulin metabolism in the brain directly and indirectly, and some drugs that lower circulating levels appear to slow cognitive decline and brain atrophy in diabetes. SUMMARY:Nonesterified fatty acids may contribute to dementia, much as they do to diabetes and cardiovascular disease. Several therapeutic agents lower circulating levels of nonesterified fatty acids and should be tested for their potential preventive effects on cognitive decline in healthy populations before irreversible neuronal attrition occurs.
Authors: Joshua I Barzilay; Alokananda Ghosh; Rodica Pop Busui; Andrew Ahmann; Ashok Balasubramanyam; Mary Ann Banerji; Robert M Cohen; Jennifer Green; Faramarz Ismail-Beigi; Catherine L Martin; Elizabeth Seaquist; José A Luchsinger Journal: J Diabetes Complications Date: 2021-09-15 Impact factor: 2.852
Authors: Carl P Walther; Joachim H Ix; Mary L Biggs; Jorge R Kizer; Sankar D Navaneethan; Luc Djoussé; Kenneth J Mukamal Journal: Am J Kidney Dis Date: 2021-02-04 Impact factor: 11.072
Authors: Neil K Huang; Mary L Biggs; Nirupa R Matthan; Luc Djoussé; W T Longstreth; Kenneth J Mukamal; David S Siscovick; Alice H Lichtenstein Journal: J Am Heart Assoc Date: 2021-11-10 Impact factor: 5.501